Impact of New Drugs on the Long-Term Follow-Up of Upfront Tandem Autograft– Allograft in Multiple Myeloma Luisa Giaccone, Andrea Evangelista, Francesca Patriarca, Roberto Sorasio, Massimo Pini, Fabrizio Carnevale-Schianca, Moreno Festuccia, Lucia Brunello, Francesco Zallio, Enrico Maffini, Paola Omedé, Sara Bringhen, Nicola Mordini, Renato Fanin, Giovannino Ciccone, Mario Boccadoro, Benedetto Bruno Biology of Blood and Marrow Transplantation Volume 24, Issue 1, Pages 189-193 (January 2018) DOI: 10.1016/j.bbmt.2017.09.017 Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions
Figure 1 Patient survival. OS (A) and EFS (B) of the “donor” and “no donor” groups from diagnosis by intention-to-treat. OS (C) and EFS (D) from second transplant of the “donor” and “no donor” groups by per-protocol analysis. (E) OS from first relapse in the allo-SCT arm and auto-SCT arm. (F) Cumulative incidence of IS discontinuation (death and relapse were considered as competitive events). Biology of Blood and Marrow Transplantation 2018 24, 189-193DOI: (10.1016/j.bbmt.2017.09.017) Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions